Cabozantinib for liver cancer after first immune therapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests the drug cabozantinib for people with advanced liver cancer (HCC) that has worsened after the first treatment with certain immune therapy combinations. It aims to see if cabozantinib can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer confirmed by tissue sample (biopsy).
- Your cancer got worse after treatment with atezolizumab plus bevacizumab or tremelimumab plus durvalumab.
- Your cancer cannot be removed by surgery or local treatments.
- You have at least one tumor that can be measured and has not been treated with local therapy, or it has grown after such treatment.
- You are in good physical condition (ECOG 0 or 1) and have adequate liver function (Child-Pugh A).
- Your blood counts and liver/kidney tests are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs (IBI310 and sintilimab) as a first treatment for advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and works better than current options.
This trial tests a new combination of chemotherapy (FOLFOX) plus atezolizumab and bevacizumab for people with advanced liver cancer that has grown after having atezolizumab and bevacizumab alone. The goal is to see if adding chemo helps stop the cancer from growing further.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests combining three drugs (atezolizumab, bevacizumab, and tocilizumab) to see if they can help people with advanced liver cancer that cannot be removed with surgery. It aims to shrink tumors and improve outcomes for patients who have not had prior systemic therapy.
This study is testing a pill called cabozantinib for people with advanced liver cancer (HCC) that has grown despite prior treatment with atezolizumab (Tecentriq) and bevacizumab (Avastin). The goal is to see if cabozantinib can help shrink or slow the cancer.
This trial studies a combination treatment for hepatocellular carcinoma (liver cancer) that cannot be removed with surgery or transplant. It adds cabozantinib and immunotherapy (ipilimumab plus nivolumab) to TACE, a procedure that delivers medicine directly to the liver tumor area.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.